Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 4,628 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Single Dose Placebo Clear all

Conditions: Atopic Dermatitis
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 42
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Long Beach, California + 39 more

Conditions: Atherosclerosis
Interventions: Darapladib; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Cognition
Interventions: Modafinil 200mg, mixed amphetamine salts, Placebo; Drug
Lead sponsor: United States Army Aeromedical Research Laboratory; Federal
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Fort Rucker, Alabama

Conditions: Hereditary Angioedema (HAE)
Interventions: Recombinant human C1 esterase inhibitor, Placebo, SHP623; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Autism
Interventions: CM-AT, Placebo; Drug
Lead sponsor: Curemark; Industry
Eligibility: 3 Years to 8 Years
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 19
States / cities: Phoenix, Arizona • Sacramento, California • San Francisco, California + 16 more

Conditions: Stroke, Acute
Interventions: Desmoteplase, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 28
States / cities: Birmingham, Alabama • Los Angeles, California • Delray Beach, Florida + 20 more

Conditions: Cancer, Depression, Anxiety
Interventions: Ketamine, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Scottsdale, Arizona • Yuma, Arizona

Conditions: Allergic Conjunctivitis
Interventions: Prednisolone Acetate 0.12% (Pred Mild®), FOV1101-00, Prednisolone Acetate 1% (Pred Forte®), Placebo; Drug
Lead sponsor: Fovea Pharmaceuticals SA; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Infertility, Pregnancy
Interventions: Crinone vaginal progesterone gel, Placebo vaginal gel; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Transient Insomnia
Interventions: Ramelteon, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 289 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2003
U.S. locations: 12
States / cities: Palm Springs, California • San Diego, California • Miami, Florida + 9 more

Conditions: Vaginal Dysbiosis, Vaginal Disease, Molecular-bacterial Vaginosis
Interventions: Probiotic Group, Placebo Group; Dietary Supplement
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Growth Hormone Deficiency
Interventions: MOD-4023, Placebo; Drug
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Cypress, California

Conditions: Obesity
Interventions: AMG 171, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 3
States / cities: Anaheim, California • Tustin, California • Miami, Florida

Conditions: Cell Migration, Cell Invasion, Exercise Recovery
Interventions: Melatonin, Placebo; Dietary Supplement
Lead sponsor: University of Central Florida; Other
Eligibility: 18 Years to 40 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Delirium, Delirium, Dementia, Amnestic, Cognitive Disorders, Delayed Emergence From Anesthesia, Cognitive Disorders
Interventions: Ramelteon, Microcrystalline Cellulose, Riboflavin 100 mg; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 65 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy, Rheumatoid Arthritis
Interventions: IA-14069, Placebo, Methotrexate; Drug
Lead sponsor: ILAb Co., Ltd.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Healthy Subjects
Interventions: TD-1439, Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Diabetes Mellitus, Type 2
Interventions: NNC0113-2023, Placebo (NNC0113-2023); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Volunteers
Interventions: REGN1193, Placebo; Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Tuberculosis Infection
Interventions: BCG (Tokyo 172) vaccine, Placebo; Biological · Drug
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 7
States / cities: New Haven, Connecticut • Washington D.C., District of Columbia • Decatur, Georgia + 4 more

Conditions: Skin Diseases, Bacterial
Interventions: Oritavancin, Placebo (D5W); Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Somers Point, New Jersey

Conditions: Healthy Volunteer
Interventions: Subcutaneous RB006 0.5 mg/kg, Subcutaneous RB006 1.0 mg/kg, Subcutaneous RB006 3.0 mg/kg, Subcutaneous RB006 2.0 mg, Placebo; Drug
Lead sponsor: Regado Biosciences, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Chemotherapy Induced Peripheral Neuropathy (CIPN)
Interventions: Calmangafodipir, Placebo; Drug
Lead sponsor: Egetis Therapeutics AB (publ); Industry
Eligibility: 20 Years to 55 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Cypress, California

Conditions: Influenza
Interventions: Subjects were administered NasoVAX high dose; Drug
Lead sponsor: Altimmune, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Rockville, Maryland

Search by objective public record fields.

Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)

Study Of The Effects Of SB 480848 (Darapladib) On The Electrical Conduction Of The Heart

Enhancing Operational Performance in Healthy Rested Soldiers With Pharmacological Stimulants

Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects

A Trial of CM-AT in Children With Autism

Study of Desmoteplase (International Nonproprietary Name [INN]) in Acute Ischemic Stroke (DIAS-2)

Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer

Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation

Sexual Absorption of Vaginal Progesterone

Efficacy of Ramelteon on Transient Insomnia in Healthy Adults

Feasibility of an Oral Intervention for Sexual Health in Transgender Men

Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers

Single and Multiple Ascending Dose Study of AMG 171 in Subjects With Obesity

This Repeated Measures Parallel-group Investigation Will Examine the Influence of Short-term Melatonin Supplementation (5mg, 3 x Day for 72 Hours) on Cellular Responses, Functional Performance and Recovery Following an Acute Bout of Dynamic Resistance Exercise in Resistance Trained Men and Women

Ramelteon in the Prevention of Post-operative Delirium

MAD Study of IA-14069

Single Ascending Dose Study of TD-1439 in Healthy Subjects

First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men.

An Ascending Single-Dose Study of the Safety, Tolerability and Bioeffect of REGN1193

Immunization With BCG Vaccine to Prevent Tuberculosis Infection

Safety of Either a Single or Two Intravenous Doses of Orbactiv in Participants With Acute Bacterial Skin and Skin Structure Infection

Safety, Tolerability and PK/PD of RB006 in a Healthy Volunteer SAD

SUNCIST: A Study of Calmangafodipir in Healthy Japanese and Caucasian Subjects

Study of the Safety and Immunogenicity of NasoVAX Extension